• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

An Animal Model of Acute and Chronic Chagas Disease With the Reticulotropic Y Strain of Trypanosoma cruzi That Depicts the Multifunctionality and Dysfunctionality of T Cells
In conclusion, during acute T. cruzi infection with the reticulotropic Y strain, immune activation leads to the generation of antigen-specific multifunctional CD4+ Th1 and CD8+ Tc1 cells and their regulation by inhibitory receptor co-expression. In contrast, during chronic T. cruzi infection, the chronicity of the infection induces a moderate inflammatory infiltrate in colon and liver tissues accompanied with poor T cell effector function that is possibly related to the co-expression of inhibitory receptors on T cells, but this phenomenon does not occur in cytotoxic CD8+ T cells. Taken together, these data supp...
Source: Frontiers in Immunology - April 25, 2019 Category: Allergy & Immunology Source Type: research

Why Science is Mistrusted
By, SAURABH JHA MD Recently, the Harvard Chan School of Public Health, in their press release, reported about the effect of surgical checklists in South Carolina. The release was titled, “South Carolina hospitals see major drop in post-surgical deaths with nation’s first proven statewide Surgical Safety Checklist Program.” The Health News Review, for which I review, grades coverage of research in the media. Based on their objective criteria, the Harvard press release would not score highly. The title exudes certainty – “nation’s first proven.” The study, not being a randomized controlled trial (RCT), though s...
Source: The Health Care Blog - April 22, 2017 Category: Consumer Health News Authors: at RogueRad Tags: Uncategorized Source Type: blogs

What Experts in Law and Medicine Have to Say About the Cost of Drugs
By ANDY ORAM Pharmaceutical drug costs impinge heavily on consumers’ consciousness, often on a monthly basis, and have become such a stress on the public that they came up repeatedly among both major parties during the U.S. presidential campaign–and remain a bipartisan rallying cry. A good deal of the recent conference named Health Law Year in P/Review, at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, covered issues with a bearing on drug costs. It’s interesting to take the academic expertise from that conference–and combine it with a bit of commo...
Source: The Health Care Blog - February 2, 2017 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Andy Oram Drug Pricing Pharma Source Type: blogs